Drew M. Pardoll

Drew M. Pardoll, MD, PhD, is Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Professor of Oncology, Medicine, Pathology, and Molecular Biology & Genetics at Johns Hopkins University School of Medicine. He is one of the founding architects of immune checkpoint biology. Dr. Pardoll discovered PD-L2, the second ligand for PD-1, in 1999 (Nat Immunol, PMID 10581246), complementing Gordon Freeman's PD-L1 discovery and completing the PD-1 pathway framework. His laboratory characterized the molecular interactions and regulatory functions of PD-L2, demonstrating its role in T cell inhibition and contributing to the scientific foundation for anti-PD-1 therapy development. Beyond checkpoint discovery, Dr. Pardoll pioneered conceptual frameworks for cancer immunotherapy. His influential reviews and research articles defined strategies for combining checkpoint blockade with vaccines, radiation, and targeted therapies. As founding director of the Bloomberg-Kimmel Institute (established 2016 with $125 million commitment), he built one of the world's leading cancer immunotherapy research centers, training the next generation of investigators and accelerating clinical translation. Elected to the National Academy of Medicine (2017) and recognized as AACR Fellow, Dr. Pardoll received the William B. Coley Award, the AAI Excellence in Mentoring Award, and multiple other honors. His discovery of PD-L2, strategic vision for combination immunotherapy, and institutional leadership have profoundly shaped the checkpoint inhibitor field.

Drew M. Pardoll医学博士、哲学博士现任约翰霍普金斯大学医学院Bloomberg-Kimmel癌症免疫治疗研究所主任以及肿瘤学、医学、病理学和分子生物学与遗传学教授。他是免疫检查点生物学的创始架构师之一。 Pardoll博士1999年发现了PD-L2，即PD-1的第二个配体(Nat Immunol, PMID 10581246)，补充了Gordon Freeman的PD-L1发现并完成了PD-1通路框架。他的实验室表征了PD-L2的分子相互作用和调节功能，证明其在T细胞抑制中的作用，并为抗PD-1疗法开发的科学基础做出贡献。 除检查点发现外，Pardoll博士还开创了癌症免疫治疗的概念框架。他具有影响力的综述和研究文章定义了检查点阻断与疫苗、放疗和靶向治疗结合的策略。作为Bloomberg-Kimmel研究所创始主任(2016年成立，承诺1.25亿美元)，他建立了世界领先的癌症免疫治疗研究中心之一，培养了新一代研究者并加速了临床转化。 Pardoll博士2017年当选美国国家医学院院士，获认AACR会士，获William B. Coley奖、AAI卓越指导奖以及多项其他荣誉。他发现PD-L2、对组合免疫治疗的战略远见以及机构领导深刻塑造了检查点抑制剂领域。